Loading...

Christopher P Evans, MD

Title(s)Professor, Urology
SchoolUniversity of California, Davis
Phone916-734-7520
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Neurotrophins and Tyrosine Kinases in Prostate Cancer
    NIH/NIDDK K08DK060748Mar 1, 2002 - Nov 30, 2006
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. de Vere White R, Lara PN, Black PC, Evans CP, Dall'Era M. Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology. J Clin Oncol. 2020 Jan 17; JCO1901731. PMID: 31951493.
      View in: PubMed
    2. Amend G, Palvolgyi R, Rodriguez VM, Bold RJ, Evans CP. A Case Series of Preoperative Endovascular Stenting in Patients Undergoing Postchemotherapy Resection of Complex Oncologic Masses. Eur Urol Oncol. 2020 Feb; 3(1):1-6. PMID: 31892469.
      View in: PubMed
    3. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 Nov 19. PMID: 31745256.
      View in: PubMed
    4. Wang Y, Huang Z, Chen CZ, Liu C, Evans CP, Gao AC, Zhou F, Chen HW. Therapeutic targeting MDR1 expression by ROR? antagonists resensitizes cross-resistant CRPC to taxane via coordinated induction of cell death programs. Mol Cancer Ther. 2019 Nov 11. PMID: 31712394.
      View in: PubMed
    5. Grewal A, Khera SS, McGahan JP, Wilson M, Loehfelm TW, Dall'Era MA, Evans CP. Utility of Intraprocedural Contrast-Enhanced CT in Ablation of Renal Masses. AJR Am J Roentgenol. 2020 Jan; 214(1):122-128. PMID: 31532258.
      View in: PubMed
    6. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Evans CP, Gao AC. Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. Am J Clin Exp Urol. 2019; 7(4):203-214. PMID: 31511827.
      View in: PubMed
    7. Cucchiara V, Yang JC, Liu C, Adomat HH, Tomlinson Guns ES, Gleave ME, Gao AC, Evans CP. GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Mol Cancer Ther. 2019 10; 18(10):1811-1821. PMID: 31341032.
      View in: PubMed
    8. Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, Zou B, Lombard AP, D'Abronzo LS, Evans CP, Gao AC. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2019 10; 18(10):1875-1886. PMID: 31308078.
      View in: PubMed
    9. González J, Gaynor JJ, Martínez-Salamanca JI, Capitanio U, Tilki D, Carballido JA, Chantada V, Daneshmand S, Evans CP, Gasch C, Gontero P, Haferkamp A, Huang WC, Espinós EL, Master VA, McKiernan JM, Montorsi F, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Hohenfellner M, Libertino JA, Ciancio G. Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. Eur J Surg Oncol. 2019 Oct; 45(10):1983-1992. PMID: 31155470.
      View in: PubMed
    10. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 Jul; 12(7):871-878. PMID: 31075528.
      View in: PubMed
    11. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 Nov; 76(5):562-571. PMID: 30928160.
      View in: PubMed
    12. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240. PMID: 30918106.
      View in: PubMed
    13. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. PMID: 30804427.
      View in: PubMed
    14. Lara PN, Evans CP. Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be. JAMA Oncol. 2019 02 01; 5(2):171-172. PMID: 30543365.
      View in: PubMed
    15. Tilki D, Evans CP. Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Eur Urol. 2019 03; 75(3):535-536. PMID: 30466892.
      View in: PubMed
    16. Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018 11 16; 9(1):4700. PMID: 30446660.
      View in: PubMed
    17. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. PMID: 30340047.
      View in: PubMed
    18. Alpajaro SIR, Harris JAK, Evans CP. Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies. Prostate Cancer Prostatic Dis. 2019 03; 22(1):16-23. PMID: 30115959.
      View in: PubMed
    19. Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, Wang BJ, Huang SH, Yang P, Yang JC, Chu CY, Hsieh CL, Sung SY, Li CF, Tepper CG, Ann DK, Gao AC, Evans CP, Izumiya Y, Chuu CP, Wang WC, Chen HW, Kung HJ. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene. 2019 01; 38(1):17-32. PMID: 30072740.
      View in: PubMed
    20. Judge SJ, Plescia TA, Bateni CP, Darrow MA, Evans CP, Canter RJ. Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia-telangiectasia. Rare Tumors. 2018; 10:2036361318789724. PMID: 30046399.
      View in: PubMed
    21. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. PMID: 30033370.
      View in: PubMed
    22. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503. PMID: 29985747.
      View in: PubMed
    23. Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2018 10; 17(10):2197-2205. PMID: 29891490.
      View in: PubMed
    24. Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888. PMID: 29801011.
      View in: PubMed
    25. Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 05 02; 10(439). PMID: 29720449.
      View in: PubMed
    26. Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP. Local treatment for metastatic prostate cancer: A systematic review. Int J Urol. 2018 05; 25(5):390-403. PMID: 29572963.
      View in: PubMed
    27. Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Ann Oncol. 2018 01 01; 29(1):23-25. PMID: 29088323.
      View in: PubMed
    28. Evans CP. Bipolar androgen therapy: an intriguing paradox. Lancet Oncol. 2018 01; 19(1):8-10. PMID: 29248235.
      View in: PubMed
    29. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). PMID: 29206995.
      View in: PubMed
    30. Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urol Oncol. 2018 02; 36(2):79.e11-79.e17. PMID: 29129353.
      View in: PubMed
    31. Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018 04; 73(4):572-582. PMID: 29129398.
      View in: PubMed
    32. Lara PN, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. JCO Precis Oncol. 2017; 2017. PMID: 29629426.
      View in: PubMed
    33. Yuh LM, Lara PN, Wagenaar RM, Evans CP, Dall'era MA, Cress R, Yap SA. A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome. Can Urol Assoc J. 2017 Sep; 11(9):E344-E349. PMID: 29382456.
      View in: PubMed
    34. Glass AS, Pugashetti NB, Dall'Era MA, Evans CP, Yap SA. Utility of Anterior Zone Biopsy in Men Enrolled in Active Surveillance for Prostate Cancer. Clin Genitourin Cancer. 2017 Jul 14. PMID: 28789835.
      View in: PubMed
    35. Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2017 10; 16(10):2257-2266. PMID: 28698198.
      View in: PubMed
    36. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. PMID: 28655541.
      View in: PubMed
    37. Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. Prostate. 2017 Jun; 77(9):1020-1028. PMID: 28485104.
      View in: PubMed
    38. Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 08; 16(8):1521-1530. PMID: 28500234.
      View in: PubMed
    39. Tilki D, Evans CP. The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy. Eur Urol. 2018 02; 73(2):176-177. PMID: 28456348.
      View in: PubMed
    40. Yang JC, Evans CP. Adjunct Screening of NKX3.1 Expression Supports 5a-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance. Eur Urol. 2017 10; 72(4):507-508. PMID: 28454662.
      View in: PubMed
    41. Rodriguez Faba O, Linares E, Tilki D, Capitanio U, Evans CP, Montorsi F, Martínez-Salamanca JI, Libertino J, Gontero P, Palou J. Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium. Eur Urol Focus. 2018 04; 4(3):435-441. PMID: 28753848.
      View in: PubMed
    42. Cucchiara V, Yang JC, Mirone V, Gao AC, Rosenfeld MG, Evans CP. Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel). 2017 Jan 16; 9(1). PMID: 28275218.
      View in: PubMed
    43. Tilki D, Schaeffer EM, Evans CP. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. Eur Urol Focus. 2016 Dec; 2(5):499-505. PMID: 28723515.
      View in: PubMed
    44. Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ. Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. Eur Urol Focus. 2016 Dec; 2(5):469-471. PMID: 28723508.
      View in: PubMed
    45. Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther. 2017 01; 16(1):35-44. PMID: 27794047.
      View in: PubMed
    46. Chandrasekar T, Pugashetti N, Durbin-Johnson B, Dall'Era MA, Evans CP, deVere White RW, Yap SA. Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? Bladder Cancer. 2016 Oct 27; 2(4):441-448. PMID: 28035325.
      View in: PubMed
    47. Dall'Era M, Evans C. Genomic and Biological Markers to Select Treatment for Patients with Prostate Cancer: Choose Wisely, My Friend. J Urol. 2017 01; 197(1):8-9. PMID: 27746279.
      View in: PubMed
    48. Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. J Surg Oncol. 2016 Nov; 114(6):764-768. PMID: 27562252.
      View in: PubMed
    49. Tilki D, Evans CP. Re: Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2016 12; 70(6):1079-1080. PMID: 27567208.
      View in: PubMed
    50. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017 02; 71(2):151-154. PMID: 27477525.
      View in: PubMed
    51. Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol. 2017 Feb; 35(2):277-283. PMID: 27306686.
      View in: PubMed
    52. Chandrasekar T, Evans CP. Autophagy and urothelial carcinoma of the bladder: A review. Investig Clin Urol. 2016 06; 57 Suppl 1:S89-97. PMID: 27326411.
      View in: PubMed
    53. Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. Corrigendum: ROR-? drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 06 07; 22(6):692. PMID: 27270780.
      View in: PubMed
    54. Klotz L, Evans CP. Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer. J Urol. 2016 08; 196(2):309-11. PMID: 27164513.
      View in: PubMed
    55. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. PMID: 27019001.
      View in: PubMed
    56. Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. ROR-? drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 05; 22(5):488-96. PMID: 27019329.
      View in: PubMed
    57. Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 10; 70(4):675-683. PMID: 27006332.
      View in: PubMed
    58. Chandrasekar T, Evans CP. Salvage radical prostatectomy: a few good men. BJU Int. 2016 Jan; 117(1):9-10. PMID: 26676680.
      View in: PubMed
    59. Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Prostate. 2016 Apr; 76(5):445-55. PMID: 26714839.
      View in: PubMed
    60. Tilki D, Evans CP. Hormonal Treatment for Nonmetastatic Disease Recurrence After Curative Treatment of Prostate Cancer: Only for a Select Few. Eur Urol. 2016 05; 69(5):821-2. PMID: 26719013.
      View in: PubMed
    61. Chan Y, Fisher P, Tilki D, Evans CP. Urethral recurrence after cystectomy: current preventative measures, diagnosis and management. BJU Int. 2016 Apr; 117(4):563-9. PMID: 26556525.
      View in: PubMed
    62. Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ, deVere White RW. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res. 2015 Dec 15; 75(24):5309-17. PMID: 26573802.
      View in: PubMed
    63. Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015 Sep 01; 13:206. PMID: 26329698.
      View in: PubMed
    64. Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC. NF-?B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Mol Cancer Ther. 2015 Aug; 14(8):1884-95. PMID: 26056150.
      View in: PubMed
    65. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015 Jun; 4(3):365-80. PMID: 26814148.
      View in: PubMed
    66. Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate. 2015 Sep; 75(13):1341-53. PMID: 25970160.
      View in: PubMed
    67. Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J Urol. 2015 Aug; 194(2):304-308. PMID: 25797392.
      View in: PubMed
    68. Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015 Apr 01; 75(7):1413-22. PMID: 25649766.
      View in: PubMed
    69. Reeves F, Murphy D, Evans C, Bowden P, Costello A. Targeted local therapy in oligometastatic prostate cancer: a promising potential opportunity after failed primary treatment. BJU Int. 2015 Aug; 116(2):170-2. PMID: 25308065.
      View in: PubMed
    70. Tilki D, Kim SI, Hu B, Dall'Era MA, Evans CP. Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review. J Urol. 2015 May; 193(5):1525-31. PMID: 25444980.
      View in: PubMed
    71. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015 Mar; 67(3):470-9. PMID: 25306226.
      View in: PubMed
    72. Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer. Oncotarget. 2014 Sep 15; 5(17):7217-59. PMID: 25277175.
      View in: PubMed
    73. Guo W, Liu R, Bhardwaj G, Yang JC, Changou C, Ma AH, Mazloom A, Chintapalli S, Xiao K, Xiao W, Kumaresan P, Sanchez E, Yeh CT, Evans CP, Patterson R, Lam KS, Kung HJ. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis. 2014 Sep 04; 5:e1409. PMID: 25188519.
      View in: PubMed
    74. Farrow JM, Yang JC, Evans CP. Autophagy as a modulator and target in prostate cancer. Nat Rev Urol. 2014 Sep; 11(9):508-16. PMID: 25134829.
      View in: PubMed
    75. Evans CP, Lara PN. Prostate cancer: Predicting response to androgen receptor signalling inhibition. Nat Rev Urol. 2014 Aug; 11(8):433-5. PMID: 25048863.
      View in: PubMed
    76. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. J Urol. 2015 Feb; 193(2):436-42. PMID: 25063493.
      View in: PubMed
    77. Thieu W, Tilki D, de Vere White R, Evans CP. The role of microRNA in castration-resistant prostate cancer. Urol Oncol. 2014 Jul; 32(5):517-523. PMID: 24935732.
      View in: PubMed
    78. Jin C, Yang L, Xie M, Lin C, Merkurjev D, Yang JC, Tanasa B, Oh S, Zhang J, Ohgi KA, Zhou H, Li W, Evans CP, Ding S, Rosenfeld MG. Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proc Natl Acad Sci U S A. 2014 Jun 24; 111(25):9235-40. PMID: 24928520.
      View in: PubMed
    79. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31; 371(5):424-33. PMID: 24881730.
      View in: PubMed
    80. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, Shariat SF, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Curr Urol Rep. 2014 May; 15(5):404. PMID: 24682884.
      View in: PubMed
    81. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3198-3210. PMID: 24740322.
      View in: PubMed
    82. Tilki D, Evans CP. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions. Can J Urol. 2014 Apr; 21(2 Supp 1):7-13. PMID: 24775718.
      View in: PubMed
    83. Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN, DeVere White RW, Gao AC, Evans CP. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014 Sep 04; 33(36):4521-30. PMID: 24662833.
      View in: PubMed
    84. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014 Mar 15; 120(6):818-23. PMID: 24258693.
      View in: PubMed
    85. Lara PN, Evans CP. Dasatinib and docetaxel in advanced prostate cancer. Lancet Oncol. 2013 Dec; 14(13):1248-9. PMID: 24211164.
      View in: PubMed
    86. Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate. 2014 Feb; 74(2):201-9. PMID: 24307657.
      View in: PubMed
    87. Guo W, Liu R, Bhardwaj G, Ma AH, Changou C, Yang JC, Li Y, Feng C, Luo Y, Mazloom A, Sanchez E, Wang Y, Huang W, Patterson R, Evans CP, Lam KS, Kung HJ. CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors. PLoS One. 2013; 8(8):e70910. PMID: 23967135.
      View in: PubMed
    88. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013 Aug 29; 500(7464):598-602. PMID: 23945587.
      View in: PubMed
    89. Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther. 2013 Sep; 12(9):1829-36. PMID: 23861346.
      View in: PubMed
    90. Tilki D, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol. 2014 Sep; 66(3):577-83. PMID: 23871402.
      View in: PubMed
    91. Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, Evans CP, Gao AC. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol. 2013 Jul; 183(1):288-95. PMID: 23790802.
      View in: PubMed
    92. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, deVere White RW, Kung HJ. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2014 May 08; 33(19):2495-503. PMID: 23728339.
      View in: PubMed
    93. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC. NF-?B2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013 Aug; 12(8):1629-37. PMID: 23699654.
      View in: PubMed
    94. Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, Shariat SF, Bochner BH. Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol. 2013 Aug; 64(2):266-76. PMID: 23648149.
      View in: PubMed
    95. Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP, Weiss RH. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 2013 Jun; 189(6):2317-26. PMID: 23079374.
      View in: PubMed
    96. Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP, Koppie TM. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol. 2012 Aug; 188(2):391-7. PMID: 22698625.
      View in: PubMed
    97. Ganti S, Taylor SL, Abu Aboud O, Yang J, Evans C, Osier MV, Alexander DC, Kim K, Weiss RH. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res. 2012 Jul 15; 72(14):3471-9. PMID: 22628425.
      View in: PubMed
    98. Kim S, Dall'Era MA, Evans CP. Economic analysis of active surveillance for localized prostate cancer. Curr Opin Urol. 2012 May; 22(3):247-53. PMID: 22388666.
      View in: PubMed
    99. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 2012; 7(3):e32832. PMID: 22479342.
      View in: PubMed
    100. Hu B, Lara PN, Evans CP. Defining an individualized treatment strategy for metastatic renal cancer. Urol Clin North Am. 2012 May; 39(2):233-49, vii. PMID: 22487765.
      View in: PubMed
    101. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012 Jul 15; 118(14):3512-8. PMID: 22180322.
      View in: PubMed
    102. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012 Jan 06; 287(2):1527-37. PMID: 22128178.
      View in: PubMed
    103. McGahan JP, Loh S, Fitzgerald E, Koppie T, Evans CP, Dall'Era M, Li CS. Pretreatment imaging can be used to select imaging guidance, ultrasound alone versus CT plus ultrasound, for percutaneous renal radiofrequency ablation. AJR Am J Roentgenol. 2011 Nov; 197(5):1244-50. PMID: 22021521.
      View in: PubMed
    104. Moul JW, Evans CP, Gomella LG, Roach M, Dreicer R. Traditional approaches to androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S485-93. PMID: 22054920.
      View in: PubMed
    105. Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer. 2012 Jun 01; 130(11):2693-702. PMID: 21792888.
      View in: PubMed
    106. Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, Evans C, Weiss RH. Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer. 2012 Jun 15; 130(12):2791-800. PMID: 21732340.
      View in: PubMed
    107. Zhu Y, Tummala R, Liu C, Nadiminty N, Lou W, Evans CP, Zhou Q, Gao AC. RhoGDIa suppresses growth and survival of prostate cancer cells. Prostate. 2012 Mar; 72(4):392-8. PMID: 21681778.
      View in: PubMed
    108. Yap SA, Schupp CW, Chamie K, Evans CP, Koppie TM. Effect of age on transitional cell carcinoma of the upper urinary tract: presentation, treatment, and outcomes. Urology. 2011 Jul; 78(1):87-92. PMID: 21601253.
      View in: PubMed
    109. Sun M, Liu C, Nadiminty N, Lou W, Zhu Y, Yang J, Evans CP, Zhou Q, Gao AC. Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate. 2012 Jan; 72(1):82-9. PMID: 21538419.
      View in: PubMed
    110. Wu JN, Meyers FJ, Evans CP. Palliative care in urology. Surg Clin North Am. 2011 Apr; 91(2):429-44, x. PMID: 21419262.
      View in: PubMed
    111. Chamie K, Kurzrock EA, Evans CP, Litwin MS, Koppie TM, Wootton-Gorges SL, Boone JM, Lara PN, Devere White RW. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer. 2011 Sep 15; 117(18):4219-30. PMID: 21412759.
      View in: PubMed
    112. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011 May; 59(5):671-81. PMID: 21296484.
      View in: PubMed
    113. Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer. 2011 Feb; 2(2):151-9. PMID: 21779488.
      View in: PubMed
    114. Wang S, Zhang H, Cheng L, Evans C, Pan CX. Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. Anticancer Res. 2010 Nov; 30(11):4573-8. PMID: 21115908.
      View in: PubMed
    115. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2012 Sep; 30(5):635-45. PMID: 20888272.
      View in: PubMed
    116. Eastham JA, Evans CP, Zietman A. What is the optimal management of high risk, clinically localized prostate cancer? Urol Oncol. 2010 Sep-Oct; 28(5):557-67. PMID: 20816616.
      View in: PubMed
    117. Chun JY, Tummala R, Nadiminty N, Lou W, Liu C, Yang J, Evans CP, Zhou Q, Gao AC. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer. 2010 Aug; 1(8):868-76. PMID: 21442031.
      View in: PubMed
    118. Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther. 2010 Jun; 9(6):1629-37. PMID: 20484016.
      View in: PubMed
    119. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q, Gao AC. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res. 2010 Apr 15; 70(8):3309-19. PMID: 20388792.
      View in: PubMed
    120. Sun M, Lou W, Chun JY, Cho DS, Nadiminty N, Evans CP, Chen J, Yue J, Zhou Q, Gao AC. Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes Cancer. 2010 Mar; 1(3):283-92. PMID: 21318089.
      View in: PubMed
    121. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, Chen NT, Ma AH, Desai SJ, Lo SH, Evans CP, Lam KS, Kung HJ. Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer. 2010 Jan; 1(1):40-9. PMID: 20811583.
      View in: PubMed
    122. Hellenthal NJ, Ramirez ML, Evans CP, Devere White RW. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy. BJU Int. 2010 Feb; 105(4):485-8. PMID: 19849694.
      View in: PubMed
    123. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res. 2009 Aug 01; 15(15):4815-22. PMID: 19638459.
      View in: PubMed
    124. Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol. 2009 Sep; 182(3):900-6. PMID: 19616245.
      View in: PubMed
    125. Hellenthal NJ, Ramírez ML, Evans CP, deVere White RW, Koppie TM. Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. J Urol. 2009 Jun; 181(6):2490-5. PMID: 19371902.
      View in: PubMed
    126. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol. 2009 Apr; 4(4):448-54. PMID: 19240653.
      View in: PubMed
    127. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. PMID: 19396016.
      View in: PubMed
    128. Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther. 2009 Mar; 8(3):665-71. PMID: 19240160.
      View in: PubMed
    129. Evans CP. SUO/SBUR 2007 annual meeting proceedings: overview. Urol Oncol. 2009 Jan-Feb; 27(1):33. PMID: 19111794.
      View in: PubMed
    130. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res. 2009 Jan 01; 69(1):151-60. PMID: 19117998.
      View in: PubMed
    131. Kung HJ, Evans CP. Oncogenic activation of androgen receptor. Urol Oncol. 2009 Jan-Feb; 27(1):48-52. PMID: 19111798.
      View in: PubMed
    132. Evans CP. Identification of molecular targets in urologic oncology. World J Urol. 2009 Feb; 27(1):3-8. PMID: 19002690.
      View in: PubMed
    133. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene. 2008 Oct 23; 27(49):6365-75. PMID: 18679417.
      View in: PubMed
    134. Ramírez ML, Nelson EC, Devere White RW, Lara PN, Evans CP. Current applications for prostate-specific antigen doubling time. Eur Urol. 2008 Aug; 54(2):291-300. PMID: 18439749.
      View in: PubMed
    135. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara DR, Mack PC, Kung HJ. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008 Apr 01; 68(7):2250-8. PMID: 18381431.
      View in: PubMed
    136. Ramírez ML, Nelson EC, Evans CP. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis. 2008; 11(3):216-29. PMID: 18227856.
      View in: PubMed
    137. Cambio AJ, Evans CP, Kurzrock EA. Non-surgical management of multicystic dysplastic kidney. BJU Int. 2008 Apr; 101(7):804-8. PMID: 18190645.
      View in: PubMed
    138. Nelson EC, Rodriguez RL, Dawson K, Galvez AF, Evans CP. The interaction of genetic polymorphisms with lifestyle factors: implications for the dietary prevention of prostate cancer. Nutr Cancer. 2008; 60(3):301-12. PMID: 18444164.
      View in: PubMed
    139. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19983-8. PMID: 18056640.
      View in: PubMed
    140. Ramirez ML, Keane TE, Evans CP. Managing prostate cancer: the role of hormone therapy. Can J Urol. 2007 Dec; 14 Suppl 1:10-8. PMID: 18163939.
      View in: PubMed
    141. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. PMID: 18272025.
      View in: PubMed
    142. Ramírez ML, Evans CP. Current management of small renal masses. Can J Urol. 2007 Dec; 14 Suppl 1:39-47. PMID: 18163944.
      View in: PubMed
    143. Evans CP. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer. Eur Urol. 2007 Oct; 52(4):1129-30. PMID: 17383082.
      View in: PubMed
    144. Nelson EC, Evans CP, Pan CX, Lara PN. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. World J Urol. 2007 Aug; 25(4):393-9. PMID: 17562051.
      View in: PubMed
    145. Cambio AJ, Ellison LM, Chamie K, deVere White RW, Evans CP. Cost-benefit and outcome analysis: effect of prostate biopsy undergrading. Urology. 2007 Jun; 69(6):1152-6. PMID: 17572205.
      View in: PubMed
    146. Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(4):331-9. PMID: 17471291.
      View in: PubMed
    147. Cambio AJ, Evans CP. Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Ther Clin Risk Manag. 2007 Mar; 3(1):181-96. PMID: 18360626.
      View in: PubMed
    148. Nelson EC, Evans CP, Lara PN. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev. 2007 May; 33(3):299-313. PMID: 17329029.
      View in: PubMed
    149. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia. 2007 Feb; 9(2):90-100. PMID: 17357254.
      View in: PubMed
    150. Nelson EC, Cambio AJ, Yang JC, Lara PN, Evans CP. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nat Clin Pract Urol. 2007 Feb; 4(2):82-94. PMID: 17287869.
      View in: PubMed
    151. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN, Evans CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(1):6-14. PMID: 17075603.
      View in: PubMed
    152. Cambio AJ, Evans CP. Minimising postoperative incontinence following radical prostatectomy: considerations and evidence. Eur Urol. 2006 Nov; 50(5):903-13; discussion 913. PMID: 16956715.
      View in: PubMed
    153. McGahan JP, Ro KM, Evans CP, Ellison LM. Efficacy of transhepatic radiofrequency ablation of renal cell carcinoma. AJR Am J Roentgenol. 2006 May; 186(5 Suppl):S311-5. PMID: 16632693.
      View in: PubMed
    154. Cambio AJ, Evans CP. Management approaches to small renal tumours. BJU Int. 2006 Mar; 97(3):456-60. PMID: 16469007.
      View in: PubMed
    155. Ok JH, Meyers FJ, Evans CP. Medical and surgical palliative care of patients with urological malignancies. J Urol. 2005 Oct; 174(4 Pt 1):1177-82. PMID: 16145365.
      View in: PubMed
    156. Ok JH, Cambio A, Lara PN, Evans CP. Is the use of anything but MVAC justified in the evidence-based medicine era? Curr Opin Urol. 2005 Sep; 15(5):312-4. PMID: 16093854.
      View in: PubMed
    157. Evans CP, Fleshner N, Fitzpatrick JM, Zlotta AR. An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU Int. 2005 Apr; 95(6):743-9. PMID: 15794775.
      View in: PubMed
    158. Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, Hall MC, Higano C, Kelly WK, Sartor O, Smith JA. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer. 2005 Jan 01; 103(1):11-21. PMID: 15558815.
      View in: PubMed
    159. Pitts WR. Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004 Dec; 172(6 Pt 1):2484. PMID: 15538302.
      View in: PubMed
    160. Busby JE, Evans CP. Old friends, new ways: revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes. Curr Opin Urol. 2004 Sep; 14(5):251-7. PMID: 15300144.
      View in: PubMed
    161. Evans CP. Evidence-based medicine for the urologist. BJU Int. 2004 Jul; 94(1):1-2. PMID: 15217418.
      View in: PubMed
    162. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004 Jun; 171(6 Pt 1):2250-4. PMID: 15126796.
      View in: PubMed
    163. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene. 2004 Mar 18; 23(12):2197-205. PMID: 14767470.
      View in: PubMed
    164. Nguyen MM, Corr AS, Evans CP. Testicular cancer metastatic exclusively to the brain and spleen. Urology. 2004 Jan; 63(1):176-8. PMID: 14751386.
      View in: PubMed
    165. Busby JE, Evans CP. Determining variables for repeat prostate biopsy. Prostate Cancer Prostatic Dis. 2004; 7(2):93-8. PMID: 14993898.
      View in: PubMed
    166. Gleave M, Evans CP. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2004; 7(4):273-6. PMID: 15592439.
      View in: PubMed
    167. Evans CP, Busby JE. The management of stage T1 grade 3 transitional cell carcinoma of the bladder. BJU Int. 2003 Sep; 92(4):345-8. PMID: 12930415.
      View in: PubMed
    168. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003 Aug; 170(2 Pt 1):498-502. PMID: 12853808.
      View in: PubMed
    169. Highshaw RA, Tanaka ST, Evans CP, deVere White RW. Is bladder biopsy necessary at three or six months post BCG therapy? Urol Oncol. 2003 May-Jun; 21(3):207-9. PMID: 12810207.
      View in: PubMed
    170. Busby E, Das S, Rao Tunuguntla HS, Evans CP. Hand-assisted laparoscopic vs the open (flank incision) approach to radical nephrectomy. BJU Int. 2003 Mar; 91(4):341-4. PMID: 12603411.
      View in: PubMed
    171. Evans CP, Tunuguntla HS, Saffarian AR, Wood CG. Does retroperitoneal lymphadenectomy for testicular germ cell tumor require a different approach in the presence of horseshoe kidney? J Urol. 2003 Feb; 169(2):503-6. PMID: 12544297.
      View in: PubMed
    172. Busby JE, Shih SJ, Yang JC, Kung HJ, Evans CP. Angiogenesis is not mediated by prostate cancer neuropeptides. Angiogenesis. 2003; 6(4):289-93. PMID: 15166497.
      View in: PubMed
    173. Gleave M, Evans CP. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2003; 6(3):200-3. PMID: 12970721.
      View in: PubMed
    174. Shih SJ, Dall'Era MA, Westphal JR, Yang J, Sweep CG, Gandour-Edwards R, Evans CP. Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue. Prostate Cancer Prostatic Dis. 2003; 6(2):131-7. PMID: 12806371.
      View in: PubMed
    175. Gleave M, Evans CP. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2003; 6(4):268-71. PMID: 14663465.
      View in: PubMed
    176. Shi XB, Di Mauro SM, Highshaw R, Deitch AD, Evans CP, Gumerlock PH, deVere White RW. Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue. Cancer Biother Radiopharm. 2002 Dec; 17(6):657-64. PMID: 12537669.
      View in: PubMed
    177. Highshaw RA, Tunuguntla HS, Perez RV, Gandour-Edwards R, Evans CP. Initial report of bladder carcinoma following combined bladder-drained pancreas and kidney transplantation. Clin Transplant. 2002 Oct; 16(5):383-6. PMID: 12225437.
      View in: PubMed
    178. Tunuguntla HS, Evans CP. Minimally invasive therapies for benign prostatic hyperplasia. World J Urol. 2002 Sep; 20(4):197-206. PMID: 12215846.
      View in: PubMed
    179. Evans CP. Follow-up surveillance strategies for genitourinary malignancies. Cancer. 2002 Jun 01; 94(11):2892-905. PMID: 12115377.
      View in: PubMed
    180. Eandi JA, de Vere White RW, Tunuguntla HS, Bohringer CH, Evans CP. Can single dose preoperative intrathecal morphine sulfate provide cost-effective postoperative analgesia and patient satisfaction during radical prostatectomy in the current era of cost containment? Prostate Cancer Prostatic Dis. 2002; 5(3):226-30. PMID: 12496986.
      View in: PubMed
    181. Gleave M, Evans C. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2002; 5(3):168-71. PMID: 12496976.
      View in: PubMed
    182. Gurunadha Rao Tunuguntla HS, Evans CP. Management of prostatitis. Prostate Cancer Prostatic Dis. 2002; 5(3):172-9. PMID: 12496977.
      View in: PubMed
    183. Innovators in Urology, 4th International Meeting. 9-11 March 2002, Miami, Florida, USA. Abstracts. Prostate Cancer Prostatic Dis. 2002; 5 Suppl 1:S1-39. PMID: 12497009.
      View in: PubMed
    184. Eandi JA, Yang JC, Evans CP. Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer. Biochem Biophys Res Commun. 2001 Nov 02; 288(3):521-7. PMID: 11676474.
      View in: PubMed
    185. Evans CP, Stapp EC, Dall'Era MA, Juarez J, Yang JC. Regulation of u-PA gene expression in human prostate cancer. Int J Cancer. 2001 Nov 01; 94(3):390-5. PMID: 11745419.
      View in: PubMed
    186. Evans CP, Elfman F, Cunha G, Shuman MA. Decreased prostate cancer cell migration by inhibition of the insulin-like growth factor II/Mannose-6-Phosphate receptor. Urol Oncol. 1997 Sep-Dec; 3(5-6):166-70. PMID: 21227140.
      View in: PubMed
    187. Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res. 1997 Aug 15; 57(16):3594-9. PMID: 9270033.
      View in: PubMed
    188. Evans CP, Gajendran V, Tewari A, Aslam K, Juster R, Gange S, Eason A, Narayan P. The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate. Br J Urol. 1996 Sep; 78(3):426-31. PMID: 8881955.
      View in: PubMed
    189. Evans CP, Swanson DA. What to do if the lymph nodes are positive. Semin Urol Oncol. 1996 May; 14(2):96-102. PMID: 8734737.
      View in: PubMed
    190. Narayan P, Tewari A, Aboseif S, Evans C. A randomized study comparing visual laser ablation and transurethral evaporation of prostate in the management of benign prostatic hyperplasia. J Urol. 1995 Dec; 154(6):2083-8. PMID: 7500464.
      View in: PubMed
    191. Evans CP, Stoller ML. The fate of the iatrogenic retroperitoneal stone. J Urol. 1993 Sep; 150(3):827-9. PMID: 8345593.
      View in: PubMed
    192. Margulies IM, Höyhtyä M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct; 1(6):467-74. PMID: 1302559.
      View in: PubMed
    193. Evans CP, Walsh DS, Kohn EC. An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1. Int J Cancer. 1991 Aug 19; 49(1):109-13. PMID: 1874563.
      View in: PubMed
    194. Skoog SJ, Evans CP, Hayward IJ, Griffin JL, Hitchcock CL. Flow cytometry of fine needle aspirations of the Sprague-Dawley rat testis: defining normal maturation and the effects of multiple biopsies. J Urol. 1991 Aug; 146(2 ( Pt 2)):620-3. PMID: 1861314.
      View in: PubMed
    195. Evans CP, Vaccaro JA, Storrs BG, Christ PJ. Suprarenal occurrence of an adenomatoid tumor. J Urol. 1988 Feb; 139(2):348-9. PMID: 3339740.
      View in: PubMed